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AbstrAct 
The cancer burden is rising globally, exerting significant 
strain on populations and health systems at all income 
levels. In May 2017, world governments made a 
commitment to further invest in cancer control as a 
public health priority, passing the World Health Assembly 
Resolution 70.12 on cancer prevention and control 
within an integrated approach. In this manuscript, the 
2016 European Society for Medical Oncology Leadership 
Generation Programme participants propose a strategic 
framework that is in line with the 2017 WHO Cancer 
Resolution and consistent with the principle of universal 
health coverage, which ensures access to optimal cancer 
care for all people because health is a basic human 
right. The time for action is now to reduce barriers and 
provide the highest possible quality cancer care to 
everyone regardless of circumstance, precondition or 
geographic location. The national actions and the policy 
recommendations in this paper set forth the vision of 
its authors for the future of global cancer control at the 
national level, where the WHO Cancer Resolution must be 
implemented if we are to reduce the cancer burden, avoid 
unnecessary suffering and save as many lives as possible.
IntroduCtIon
Historically, cancer has received alarmingly 
little attention from global policymakers 
and donors in spite of the significant and 
increasing health burden. Approximately 
8.8 million people are dying each year of 
cancer, amounting to one out of six deaths 
globally and far exceeding the number of 
deaths from HIV/AIDS, malaria and tuber-
culosis combined.1 The disease burden is 
greatest in low-income and middle-income 
countries (LMICs), where 75% of cancer 
deaths occur and the number of cancer cases 
is rising most rapidly.
Importantly, cancer incidence is estimated 
to double by 2035.2 The greatest increase 
in cancer cases is expected in LMICs due to 
demographic changes, such as ageing of the 
population, and increasing exposure to risk 
factors. However, health systems, particu-
larly those in LMICs, are not well prepared 
or equipped to manage this growing burden, 
and current budgetary allocation and global 
resource mobilisation are markedly insuf-
ficient. While an estimated 60% of cancer 
cases occur in LMICs, only 5% of global 
spending on cancer is directed to these 
countries.3 Furthermore, only 1% of global 
health financing is directed to non-com-
municable diseases (NCDs), which include 
cancer, and is vastly disproportionate to the 
actual NCD burden.4 The growth in oncology 
cost is expected to rise 7%–10% annually 
throughout 2020, when global oncology costs 
will exceed $150 billion.5
The consequence has been significant phys-
ical, financial and emotional strain on indi-
viduals and families suffering from cancer 
around the globe. Prolonged disability and 
premature mortality have a substantial 
economic impact. The high direct and indi-
rect economic costs of cancer need particular 
considerations, and a substantial portion of 
cancer patients are not accessing or receiving 
adequate care mainly because of weak health 
systems, inadequate national services, dispar-
ities in access to cancer care and high finan-
cial costs. In addition, there is a lack of public 
information and awareness on how to recog-
nise the signs that a person has cancer. This 
delays timely access to care, resulting in late-
stage cancer diagnoses and premature cancer 
mortality.
The World Health Assembly (WHA) is 
the governing body of WHO, and it meets 
every year in May in Geneva. At last year’s 
70th WHA, 194 governments from around 
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the world came together and resoundingly passed the 
Resolution Agenda Item 15.6 (WHA70.12), known as 
the ‘Cancer Resolution’. The resolution states in no 
uncertain terms that cancer prevention and control is a 
significant and growing public health concern requiring 
attention, investment and prioritisation by governments 
and international organisations at the national and global 
level.6 This Cancer Resolution is a milestone achievement 
because until now cancer has not been either high or 
visible on the global health agenda. Therefore, we must 
harness this opportunity and act through united global, 
national and local efforts to assure its implementation. 
One of the resolution’s main goals is timely access to 
cancer treatment and care for all, upholding the 1948 
United Nations Universal Declaration on Human Rights, 
which states that everyone has the basic right to medical 
care to assure the health and well-being of themselves and 
their families.7
Addressing the growing cancer burden as a public 
health priority is challenging. Cancer is a not a single 
disease but rather a multitude of diseases. Many cancers 
are heterogenous in their characteristics, with hundreds 
of histological and biological subtypes. It requires specific 
diagnostic and therapeutic strategies, and a qualified 
workforce to implement them, coupled with the imper-
ative need of coordinated multidisciplinary patient care. 
Additionally, while cancer programmes can build on the 
progress made within the global NCD agenda, there are 
specificities in cancer prevention and control that require 
particular attention. For example, cancer is not only an 
NCD, but also a ‘communicable’ disease. Up to 25% of 
cancers in LMICs can be attributed to communicable 
diseases such as hepatitis B and C (hepatocellular carci-
noma), human papilloma virus (HPV) (cervical cancer) 
and parasitic infections, such as liver flukes and schistoso-
miasis (biliary and bladder cancers).8 To address hepatitis 
B and HPV through the implementation of nationwide 
vaccination programmes requires synergies across 
disciplines.
Strategies to address the global cancer burden must be 
tailored to the local reality. It must account for a country’s 
most prevalent cancer types and be tackled according to 
the country’s available resources. To properly allocate 
resources, accurate comprehensive cancer registries are 
essential to provide information on the epidemiology of 
cancer in the country. Decisions must be based on the 
best available evidence and accurate epidemiological 
data, addressed within a national cancer control plan 
(NCCP). While >70% of countries have NCCPs, not all of 
them are well funded and implemented.9 The successful 
implementation of any NCCP requires involvement of all 
stakeholders, including health policymakers, academic 
organisations, healthcare professionals, civil society, 
patients, industry and the media because the status quo 
is not working.
need for action
Change is needed, and the United Nations’ ‘2030 Agenda 
for Sustainable Development’ has defined the target. 
Goal 3 of the Sustainable Development Goals (SDGs) 
seeks to ensure healthy lives and to promote well-being 
for all people at all ages. Two particular targets within 
SDG number 3 relate to cancer: (1) the reduction in 
premature mortality from NCDs, including cancer, by 
one-third by 2030; and (2) achieve universal health 
coverage, including financial risk protection, access to 
quality essential healthcare services and access to safe, 
effective, quality and affordable essential medicines and 
vaccines for all.10
This paper articulates the vision of the participants of 
the 2016 European Society for Medical Oncology (ESMO) 
Key messages
What is already known about this subject?
 ► Global cancer control has been a growing priority of governments 
globally and the World Health Organisation (WHO) as reflected 
in numerous guidance documents and commitments. WHO 
and  International Agency for Research on Cancer have produced 
technical guides for the development and implementation of 
cancer prevention and control activities ranging from identifying 
carcinogens to access to essential medicines and palliative care. 
Additionally, countries and WHO have made commitments to global 
cancer control such as the 2013–2020 WHO Global Action Plan 
on the Prevention and Control of Noncommunicable Diseases, 
the 2030 UN Agenda for Sustainable Development and most 
importantly the 2017 World Health Assembly (WHA) Resolution on 
Cancer prevention and control within an integrated approach. The 
guiding principles of these WHO and UN documents is that health 
is a basic human right, and in order to respect that right, health 
services need to be provided through a universal health coverage 
system that leaves no one behind.
What does this study add?
 ► This paper looks at the 2017 World Health Assembly Resolution on 
Cancer prevention and control within an integrated approach from 
a public policy perspective. It reflects the vision of the European 
Society for Medical Oncology’s future oncology leaders on 
the resolution's implementation at the national level. It addresses 
the key topics of the Cancer Resolution like cancer prevention, 
timely access to treatment and care, palliative and survivorship 
care, and comprehensive data collection through robust cancer 
registries. It provides a set of concrete actions and policy 
recommendations to improve patient care. This study is the first 
to articulate the response and commitment of leading experts in 
cancer to advance global cancer control through the framework of 
the 2017 WHA Cancer Resolution and universal health coverage.
How might this impact on clinical practice?
 ► Public policy has a tremendous effect on the profession and 
practice of medical oncology. National health systems are created 
through public health policies. The way that health systems are 
structured, the services that they offer, the competencies and 
training requirements of their workforce, the quality standards of 
their treatment of patients, and the robustness of cancer registry 
data are all public policy issues aimed at improving patient 
outcomes. The global policy recommendations set out in this paper 
can harmonise efforts across the globe to address critical issues in 
cancer management with sustainable solutions.
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Leaders Generation Programme11 to address the chal-
lenges facing cancer care globally. We aim to propose a 
strategic framework at the national level to achieve effec-
tive cancer care for all, based on the concept of universal 
health coverage and the commitments made by 194 coun-
tries to implement the 2017 WHO ‘Cancer Resolution’. At 
the end of each section of the paper, we provide national 
policy recommendations that are in line with our vision, 
ESMO initiatives, and the 2017 WHO Cancer Resolution. 
Our vision is supported by the ESMO leadership and the 
ESMO Public Policy Steering Committee.
The ESMO Leaders Generation Programme was 
launched in 2016 and gathered outstanding early career 
oncologists from all over Europe. This programme is 
designed to train the next generation of oncology leaders 
to take on the responsibility of advancing the practice 
and profession of medical oncology worldwide with the 
goal of improving access to high-quality cancer care for 
everyone everywhere. In table 1 we identity examples of 
key strategic priority actions at the national level for poli-
cymakers, health planners, clinicians, patients and civil 
society to achieve the goal of equal access to cancer care 
worldwide. This needs to be a priority for the future of 
oncology, and we need to advocate for it - for our patients 
at home and for patients in clinics across the world. We 
understand that global cancer policies are essential; 
however, they will only be successful if they are imple-
mented within each country at the national, regional and 
local levels.
developing a framework for action
Inequities in cancer care are widespread between and 
within countries, and health systems must be reoriented 
around the patients and their needs to improve cancer 
outcomes for all. Up to 50% of all premature deaths 
from NCDs, including cancer, have been associated with 
inadequate health systems that do not respond effec-
tively and equitably to healthcare needs of the popula-
tion.12 
Therefore, a significant proportion of cancer-related 
deaths can be avoided if action is taken and an adequate 
restructuring of health systems is implemented. This will 
require training in the organisation of cancer services 
and how to deliver them effectively and efficiently with a 
country’s available human and financial resources. It will 
also require strengthening of health information systems 
along with a political commitment to timely patient 
access to essential cancer services. WHO’s six building 
blocks and overall goals for health systems are reported 
in  figure 1 .
Table 1 Summary of priority actions of key national stakeholders in cancer control to reduce inequalities in access to cancer 
care
Stakeholder group Sample national priority actions
National policymakers  ► Develop comprehensive national cancer control programmes, plans and strategies
 ► Facilitate access to cancer care for all by prioritising cost-effective programmes and 
financing a basic package of cancer services
 ► Create a favourable policy environment to reduce exposure to carcinogens
 ► Maximise cancer prevention interventions (eg, tobacco control, vaccines)
 ► Promote access to palliative care and pain management
 ► Promote access to rehabilitation services and psychosocial support
 ► Assure the existence of a national cancer registry and that the data in that registry are 
comprehensive and accurate
Regional or facility health planners  ► Coordinate cancer services between facilities
 ► Promote multidisciplinary care
 ► Enable the training of the oncology workforce
 ► Develop programmes and protocols that optimise benefits and avoid, or reduce, 
harmful or unnecessary cancer interventions (eg, extraneous imaging tests)
Academic societies  ► Advance the art, science and practice of oncology
 ► Support development and dissemination of norms and standards for quality cancer 
care
 ► Develop programmes to assure a well-trained oncology workforce
 ► Promote awareness of cancer as a global public health priority
Clinicians/providers  ► Pursue and provide the highest quality cancer care for all
 ► Ensure coordination of services between providers and delivery of services within a 
multidisciplinary team
 ► Support and adhere to evidence-based clinical practice guidelines and research
Patients and civil society  ► Define the goals of cancer management and outcomes for patient monitoring and 
evaluation
 ► Advocate for strong policies and programmes to support cancer control
 ► Advocate for rehabilitation services, psychosocial support and equal access to high-
quality care
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To have a measurable impact on the lives of cancer 
patients, an approach is needed that links public health 
policies to clinical outcomes. Oncologists are well posi-
tioned as leaders in delivering clinical cancer services. 
They can provide valuable input to guide public health 
strategies and work with policymakers to develop and 
implement a robust health systems framework. Access 
to quality cancer care should be based on the three 
WHO principles of universal health coverage outlined in 
figure 2, which are (1) reduce direct costs, (2) improve 
population coverage and (3) promote service coverage.
Dimension 1: address the financial burden of cancer diagnosis and 
treatment (direct costs)
The high direct and indirect economic cost of cancer 
needs particular attention because a substantial portion 
of patients with cancer are not accessing or receiving 
adequate care because of its financial burden. There are 
considerable variations in access to, and financing of, 
cancer care across different countries, with differences 
in public contributions (eg, government agencies and 
donors) and household ‘out-of-pocket’ expenses. LMICs 
are particularly vulnerable as only about 5% of global 
cancer funds are directed towards those countries, placing 
a significantly greater burden on individual patients and 
households.13
The reasons that low proportions of total cancer costs 
are covered by public contributions are multifactorial. 
First, a significant gap exists between the health spending 
of developed and less developed countries. For example, 
in the financial year 2015–2016, 145 billion British pounds 
Figure 1 The six building blocks of a health system that must be considered for effective, comprehensive delivery of cancer 
services. Taken from: Everybody’s business—strengthening health systems to improve health outcomes.55
Figure 2 Three dimensions to consider when moving towards universal coverage.56
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were allocated to health services in the UK (18.7% of 
total governmental budget).14 In less developed coun-
tries, or fragile states, government budgets are already 
limited, and resources are spent on competing public 
needs such as education or security. Therefore, health-
care costs are covered by out-of-pocket expenditure by 
the patients. In some war-torn countries, government 
expenditure on health is <1% of the budget allocated 
for security.15 16 Therefore, out-of-pocket expenditures 
represent a significant percentage of total health expen-
diture—an estimated 37%–50% of total health expendi-
ture in low-income and lower-middle-income countries.17 
Second, prices may partially explain the differences in 
availability of cancer medicines and disparity in cancer 
care.18 In a recent study, despite generally lower prices 
of medicines in less developed countries, medicines were 
less affordable because of lower income per capita.19 Per 
capita expenditure on health (purchasing power parity) 
is $92 in low-income countries compared with $5205 in 
high-income countries.17
To overcome high direct costs that function as a 
barrier to universal cancer care, a multisectoral strategy is 
required. We need to raise awareness that cancer is not a 
death sentence, and that cancer treatment can be imple-
mented in a cost-effective manner. We need to foster 
this recognition in governments—in both the Ministry 
of Finance and the Ministry of Health, as well as in the 
general public. Current pooled funds (figure 2, blue box) 
should be directed towards priority ‘best buys’ in cancer 
control, which are cancer interventions that are cost-ef-
fective.20 Cancer control programmes should be selected 
recognising the infrastructure facilities required for their 
effective delivery. For example, breast cancer screening 
should not be prioritised until there is adequate health 
system capacity to treat the diagnosed cases—including 
trained pathologists and radiologists.21
Generally, WHO estimates that between 20% an 40% of 
health expenditure is wasted.22 By reducing low-impact, 
high-cost expenditures in cancer care, resources can be 
reallocated to a package of essential cancer services at low 
cost. By identifying and resolving inefficiencies and unnec-
essary expenditures—for example, performing a positive 
emission tomography scan on a cancer patient with early-
stage disease—financial resources can be redirected for 
necessary diagnostic and treatment expenditures.
Recommendations
1. Prioritise efficient use of national resources
 – Invest in cancer prevention
 – Promote early diagnosis among public and general 
practitioners to identify cancer at an earlier stage 
when treatment is more effective and less expensive
 – Pool procurement of essential medicines and 
devices to reduce costs
 – Identify priority cancer treatment regimens that 
provide similar outcomes but at significantly lower 
costs
 – Consider the use of generics and biosimilars
2. Assure equity in cancer care that is sustainable, af-
fordable and available to everyone
 – Medical professionals should advocate for, and 
with, patients with cancer, in hospitals, in the 
media, and at national and global levels, for cancer 
care that is sustainable, affordable and available to 
everyone
Dimension 2: promote full population coverage by addressing 
geographic, financial and sociocultural barriers (population 
coverage)
There are two competing needs in promoting population 
coverage based on geographical access to cancer care. We 
need to reconcile the differences in services provided at 
centralised facilities and those provided in rural areas. 
The services at high-volume centralised facilities are 
generally more effective with better outcomes; contrasted 
against the decentralised services with local care, which 
generally facilitate accessibility of services and early diag-
nosis of cancer in more rural areas.23–25
Another important objective is to promote health 
coverage at primary and secondary levels because the vast 
majority of patients enter the health system at these points. 
Services at these levels include core interventions ranging 
from counselling for cancer prevention to early diagnosis 
and palliative care.26 In addition, where cancer screening 
programmes exist, participation in those programmes 
depends on timely access to primary care and cancer 
services.27 Without strong primary and secondary care 
services, patients with cancer will not be able to access 
specialised services in a timely manner, resulting in the 
majority of patients presenting with advanced disease.
Gaps in population coverage can arise because of differ-
ential access to insurance schemes, sociocultural factors 
such as age and poverty, and other barriers to access care. 
For example, cancer centres and advanced therapies may 
exist in a capital city but are not generally available for the 
majority of the population of a country who live in other 
areas. Strategies are needed to extend coverage to those 
who are currently unable to access care.9
In line with the 2017 WHO Cancer Resolution, ESMO is 
addressing the needs of specific vulnerable patient popu-
lations. For example, the treatment of elderly patients is 
addressed in the ESMO Handbook on Cancer in the Senior 
Patient28; ESMO leads the Rare Cancers Europe29 initia-
tive for people with rare cancers; and ESMO has a joint 
working group with the European Society for Pediatric 
Oncology for the treatment of adolescents and young 
adults.30
Recommendations
1. Adapt the organisation of cancer care to promote full 
population coverage
2. Assure comprehensive cancer services are acceptable 
and applicable to a country’s entire population
3. Strengthen regional and subregional partnerships for 
cancer management and improve coordination of ser-
vices as well as geographic accessibility
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 – Create a national network connecting rural practices 
to a large cancer centre which covers all regions in a 
country and includes pathological diagnosis as well 
as treatment decisions
 – Cancer experts can travel as visiting physicians to 
less-populated areas, with general practitioners 
instructed on how to monitor and follow patients in 
between their visits
 – Patient cases can be reviewed by multidisciplinary 
tumour boards who travel to various locations and 
discuss with local physicians difficult or complex 
cases
 – Communication between urban and rural areas can 
take place regularly by teleconferences or online via 
telemedicine
4. Provide for the long-term care needs for all patients 
with cancer including vulnerable populations
 – Provide direct diagnosis and treatment 
infrastructure, particularly in rural regions, to 
assure earlier diagnosis of cancer, yielding better 
outcomes and higher return on investments
5. Assure all patients have enough insurance coverage 
for adequate cancer care
Dimension 3: strengthen systems to provide essential services 
(service coverage)
NCCPs aim to decrease incidence, increase disease cure 
rates, prolong life and improve patients’ quality of life by 
identifying priority services to be provided and covered. 
The most cost-effective way of reducing the cancer burden 
is by enhancing awareness and implementation of preven-
tion programmes. In spite of maximal prevention efforts, 
>8 million people will develop cancer—investment in 
cancer management and treatment is therefore crucial. A 
critical strategy in cancer planning is to devise a stepwise 
approach on how to include new cancer service bundles, 
taking into consideration the resource availability of 
the local setting. For example, a first step could be to 
agree on national cancer bundles with centres of excel-
lence and affiliated clinics. These bundles would serve 
as the foundation of a country’s initial cancer service 
coverage.31 32 Prerequisites for adopting new cancer 
services may include the development of cancer manage-
ment protocols that are adapted to the national setting 
or competency training for healthcare providers. In addi-
tion, service coverage should be based on evidence-based 
guidelines and policies.
The development of NCCPs is only the first step in 
comprehensive cancer control. Implementation of the 
plan includes providing adequate financial support, 
information dissemination, public engagement, respon-
sible leadership and routine monitoring and evaluation. 
In lower-resource settings, national cancer controls plans 
should prioritise high-impact packages of services—that 
is, those assessed as very cost-effective and essential.33 34 
In addition, critical cancer services, such as pathology 
and palliative care, must be available before considering 
advanced, high-cost interventions.
Expanding the availability of essential cancer treatment 
packages has been shown to produce significant health 
and economic benefits.35–37 New innovative medicines 
can further contribute to increasing the cure rate and 
number of cancer survivors. However, these new medi-
cines must be evaluated within the context of national 
budgets and the financial protection of patients. The 
2013–2020 WHO Global NCD Action Plan calls for at 
least 80% access to essential medicines by 2025. Basic 
systemic therapy should be considered in cancer pack-
ages for universal health coverage. However, the majority 
of low-income and lower-middle-income countries do 
not have access to subsidised chemotherapy.9 Ensuring 
accessible cancer treatment generally requires that medi-
cines are included in insurance coverage packages at 
the governmental level, and that those medicines are 
also routinely available at the facility level. Significant 
gaps in the access and availability of medicines, quality 
cancer surgery and radiotherapy can result in poor clin-
ical outcomes for patients.38 Gaps in access to high-quality 
multimodality treatment result in millions of lives being 
lost.
Finally, universal coverage schemes are needed for palli-
ative care because it is a vital component of comprehen-
sive care throughout the life course, and it is consistent 
with the 2014 WHA Resolution 67.19 on improving access 
to palliative care.39 Despite widespread recognition of the 
importance of palliative care, an estimated 5.5 billion 
people have no adequate access to pain medication.40 
Currently, only 41% of countries reported palliative care 
was available in primary healthcare, and 43% reported 
routine access to morphine.9 Using standards derived 
from WHO and the International Narcotics Control 
Board, ESMO performed European and global studies 
that demonstrated that formulary deficiencies and exces-
sive regulatory barriers interfere with appropriate access 
to opioids, and therefore patient care, in many countries. 
To address this issue, ESMO, together with the interna-
tional palliative care community, has provided countries 
with 10 recommendations to reduce barriers in access to 
opioids for legitimate scientific and medical use that can 
be accessed from the ESMO website.41–43
Recommendations
1. Provide comprehensive, resource-appropriate and 
evidence-based cancer service packages
 – This requires effective planning and implementation 
of national cancer control programmes based 
on epidemiological profiles. The 2017 Cancer 
Resolution mandates WHO to develop or adapt a 
plan of stepwise, and resource-stratified, guidance 
to define such packages, leveraging the work of 
other organisations such as ESMO.
2. Assist health planners by providing tools to help deter-
mine the value of cancer care
 – To this end ESMO has developed a tool called 
the ESMO Magnitude of Clinical Benefit Scale. 
This dynamic tool provides health technology 
Open Access
7Prager GW, et al. ESMO Open 2018;3:e000285. doi:10.1136/esmoopen-2017-000285 Prager GW, et al. ESMO Open 2018;3:e000285. doi:10.1136/esmoopen-2017-000285
assessment bodies with a resource to prioritise the 
reimbursement of newly licensed medicines based 
on their incremental clinical benefit to patients.44 45
3. Make accessible to all patients in the country the can-
cer treatment regimens included in the national clini-
cal practice guidelines
4. The Cancer Resolution calls on WHO to support im-
plementation of cost-effective interventions, harmo-
nising and aligning the guidance provided by WHO 
with the clinical practice guidelines of international 
organisations such as ESMO46 47
5. Reduce the barriers of access to cancer medicines, and 
as a minimum, make those on the WHO Model List of 
Essential Medicines available and affordable to every-
one
 – ESMO’s European and International Anti-Neoplastic 
Medicines Surveys 2014–201638 48  were led by the 
ESMO Global Policy Committee and provided 
authorities with data on the actual availability of 
licensed antineoplastic medicines when prescribed. 
In many countries, especially LMICs, some cancer 
medicines—and even those that are on the WHO 
Model List of Essential Medicines49—were not 
available and/or affordable for everyone. Following 
on the results of those surveys, ESMO created the 
Cancer Medicines Working Group to work with 
global stakeholders and address topics related 
to inexpensive, essential cancer medicines, as 
well as expensive, innovative cancer medicines. A 
key achievement of the Working Group was the 
publication in May 2017 of a report by the Economic 
Intelligence Unit and ESMO, which set out a list of 
six policy recommendations on how to avoid and 
manage cancer medicine shortages in Europe.50
6. Develop cancer registries and health information 
systems that collect standardised data which is com-
prehensive and accurate, so that decision-makers can 
make informed and evidence-based policy decisions
 – Cancer registry information on incidence and 
survival are necessary to determine the service 
capacities required of primary, secondary and 
tertiary health facilities. Cancer registries should 
exist in every country, and the data should be 
collected in a standardised format, both for early 
and advanced stages of the disease. The 2017 WHO 
Cancer Resolution mandates data collection to 
measure inequalities in cancer care in order to 
guide future policies and plans.
Framing: the importance of high quality
In cancer care, universal health coverage and access must 
be framed by quality. People living with cancer can be 
free of financial, geographic or coverage barriers, but if 
that individual receives low-quality treatment, then there 
is no significant value to access and universal health 
coverage. The six dimensions of quality as defined by 
WHO include that care is (1) effective (evidence-based), 
(2) efficient (maximises resource use), (3) accessible 
(timely, geographically reasonable where skills are appro-
priate), (4) acceptable and patient-centred (accounting 
for patient preferences), (5) equitable (without variation 
in quality because of any characteristic) and (6) safe.51 
There are obstacles to these six quality dimensions for 
cancer diagnosis and treatment, and three key levels 
should be considered to improve quality: (1) policy, (2) 
health service provision and (3) community and service 
users (figure 3).
Unfortunately, for most countries, there remains a 
significant gap between the demand for evidence-based 
data and the availability of that data, which is required 
to support decision-making and ensure high-quality 
outcomes. At the policy level, it is important that people 
with expertise support decision-making to establish high-
quality cancer-related health programmes and consider 
innovative approaches and organisational structures. A 
strengths, weaknesses, opportunities and threats (SWOT) 
analysis can facilitate performance assessment and iden-
tify metrics in order to track quality over time. A compre-
hensive situational or SWOT analysis is the foundation for 
rational national cancer care programmes. Measurements 
should be directly linked to interventions or outcomes. 
Analyses and metrics should also integrate the patient 
perspective assessed through ‘patient-reported outcome 
measures’ and ‘patient-reported experience measures’. 
However, in addition to SWOT analyses and patient-re-
ported information, greater community engagement 
and empowerment is needed in local and national policy 
decision-making.
High quality is also necessary at the provider level and 
must be a tenet for all providers in the cancer continuum, 
who are defined as ‘all people engaged in actions whose 
primary intent is to enhance health’.52 Numerous studies 
show evidence of a direct and positive link between the 
availability of health workers and population health 
outcomes.52 Currently, many countries lack the human 
resources needed to deliver basic cancer interventions. 
Possible underlying reasons for this include limited 
training capacity, migration of health workers within and 
Figure 3 Process of quality improvement, roles and 
responsibilities. Taken from WHO Quality of Care: A Process 
for Making Strategic Choices In Health Systems.51
Open Access
8 Prager GW, et al. ESMO Open 2018;3:e000285. doi:10.1136/esmoopen-2017-000285
across countries, a poor mix of professional skills, and 
demographic imbalances.
Recommendations
1. Mobilise sustainable domestic human resources able 
to deliver high-quality cancer care
 – Human Resource Information Systems may be 
useful in the development of a platform for 
healthcare workers and resource distribution. For 
workforce training, a Global Curriculum in Medical 
Oncology has been developed by ESMO and the 
American Society of Clinical Oncology to define 
the core competencies required for the provision 
of cancer services.53 Participation in international 
collaborative networks can augment current 
workforce capacity through continuous knowledge 
interchange. Greater evidence is needed to enable 
adequate numbers of trained health workers to 
provide high-quality services at the right place and 
at the right time.
2. Encourage international collaborative projects among 
healthcare professionals to foster excellence
 – International collaborative projects can create a 
scientific network resulting in improved quality of 
care and knowledge, and foster an exchange of 
innovative ideas. ESMO is an international society 
with European roots and a global outreach, and can 
encourage such collaboration by bringing oncology 
professionals together, by facilitating educational 
events, and by engagement with partner societies 
to augment the quality of cancer services. 
Strong collaboration is also needed to generate 
high-quality standards of cancer care, recognising 
variations that exist between and within countries. 
High quality must remain a foundational tenet in 
cancer control—it is more than a policy, it is an oath 
to our patients and communities.
ConClusIon
The 2017 WHO Cancer Resolution is a landmark decla-
ration in cancer prevention and control, building on 
commitments made by 194 countries to reduce the burden 
of NCDs and to provide healthcare for all. Governments 
have been made aware that cancer care is an important 
health policy issue at the global level. Targets on access 
to care and mortality reduction have been defined in the 
2013–2020 WHO NCD Global Action Plan and the United 
Nations’ 2030 Agenda for Sustainable Development. 
Action is now needed to realise the goals articulated in 
these commitments and to implement appropriate poli-
cies and programmes for cancer control.
While in some settings significant progress has been 
made in the management of particular cancer types, the 
disease has proven to be complex, heterogeneous and 
therapeutically elusive. The use of modern, effective, 
yet expensive, anticancer treatments must be juxtaposed 
against the current gaps in access to high-quality cancer 
care. Significant disparities in cancer management exist 
and are arising in many settings globally. A high propor-
tion of populations are not able to access basic health 
services, significant deficits exist in trained human 
resources, and there are inadequate funds to finance the 
provision of basic cancer treatments like antineoplastic 
compounds, opioids, and radiation therapy.
In light of the magnitude of this challenge, joint efforts 
from WHO, in collaboration with dedicated cancer 
organisations like ESMO, are mandatory. The 2016 
ESMO Leaders Generation Programme participants 
heed this call and have made a commitment to action, 
recognising that as clinicians we have an independent 
position from other stakeholders, and therefore need to 
advocate for the best possible outcomes for our patients. 
As a society, ESMO has committed to global cancer care 
and has been collaborating with WHO for many years 
on joint work packages through its ‘official relation 
status’.54
The history of cancer dates back over four millennia. 
However, we are at a critical juncture—the pace of change 
is rapid and promising. But we must remember that 
our success is framed by the commitments made in the 
United Nations’ 2030 Sustainable Development Goals, to 
assure health and well-being for everyone at every stage 
of life. In this bold United Nations declaration, which will 
be remembered many years from now, we must see every 
patient with cancer as our own patient and ensure access 
and high-quality cancer care for all.
summary of recommendations 
1. Prioritise efficient use of national resources in a way 
that assures equity in cancer care that is sustainable, 
affordable and available to everyone
2. Adapt the organisation of cancer care and the oncol-
ogy workforce to promote full population coverage of 
high-quality comprehensive cancer services, including 
geographic accessibility
3. Strengthen regional and subregional partnerships for 
cancer management, as well as international collabo-
rative projects
4. Assist health planners by providing tools to help deter-
mine the value of cancer care
5. Provide comprehensive, resource-appropriate and ev-
idence-based cancer service packages that include the 
cancer regimens of national clinical practice guide-
lines
6. Provide for the long-term care needs for all patients 
with cancer, including vulnerable populations
7. Assure all patients have enough insurance coverage 
for adequate cancer care
8. Develop cancer registries and health information 
systems that collect standardised data which is 
comprehensive and accurate so that decision-makers 
can make informed and evidence-based policy 
decisions
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